

Clinical Impact of OCT-Guided PCI

2015. 12. 4

Eun-Seok Shin MD,PhD

Division of Cardiology,

Department of Internal Medicine

Ulsan University Hospital



University of Ulsan College of Medicine

Predictors of Stent Failure: early thrombosis, restenosis

Minimum lumen area
Stent underexpansion
Edge dissection
Residual stenosis
Tissue protrusion
Large plaque burden
Geographic miss etc...

IVUS data!

IVUS & OCT






High-definition
visualization

IVUS & OCT

Reducing death, MI, TLR
stent thrombosis after PCI

So What?



OCT-guided PCI

OCT Imaging

Pre-Procedure

Assess lesion characteristics
(plaque composition, culprit
lesion, stenosis severity)

Lesion assessment

Peri-Procedure

Stent Deployment
(Stent sizing, Determine
expansion/ MSA/ apposition)


Stent assessment

Post-Procedure

Assess complication (identify
edge dissection, tissue
protrusion, thrombosis)
Confirm procedural success

Complication assessment

Acute vessel wall injury after stenting



Tissue prolapse: 100%
Intrastent dissection: 92%
Edge dissection: 28%
ISA: 64%
Thrombus: 44%

→ No associated with clinical outcome

ILUMIEN I

Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention – Stage I

418 pts prospectively enrolled

35 sites in North America, EU, Asia and Australia

Patients with stable angina, unstable angina or NSTEMI plus at least 1 angiographically significant stenosis (>50% by visual estimation) in ≥ 1 native coronary artery

Mandatory use of FFR and OCT pre and post PCI;
PCI strongly recommended for $FFR \leq 0.80$

Clinical FU at 30 days, 1 year

Rates and types of abnormal findings by post-PCI OCT

OCT variables	All abnormalities by core Laboratory, n/N	Rate (%)	Abnormalities deemed unsatisfactory by operator, n/N	Rate (%)
Edge dissection	107/388	27.6	11/408	2.7
Malapposition	126/392	32.1	59/408	14.5
Under-expansion	159/385	41.3	31/408	7.6
Edge dissection and malapposition	34/388	8.8	2/408	0.5
Edge dissection and under-expansion	35/385	9.1	2/408	0.5
Malapposition and tissue protrusion	44/392	11.2	2/408	0.5
Edge dissection, malapposition, and under-expansion	14/385	3.6	0/408	0
Thrombus or tissue protrusion ^a	100/392	25.5	4/408	1.0

*Edge dissection >180° in more than five frames


*Significant malapposition defined as >200 micron in at least five consecutive frames

*Thrombus and/or tissue protrusion on OCT causing flow reduction (i.e. TIMI < 3 and/or obstruction visible by angiography).

*Under-expansion ≥30% by OCT compared with reference distal lumen area and when quantitative coronary angiogram (QCA) shows >20% in-stent residual diameter stenosis.


Impact of OCT on PCI

Pre-PCI (n=467 lesions)



Selecting different stent lengths
(shorter in 25%, longer in 43%).

Post-PCI (n=467 lesions)



Additional in-stent post-dilatation (81%)
Placement of new stents (12%)

Post hoc analysis

MACE at 30 days: death 0.25%, MI 7.7%, repeat PCI 1.7%, and stent thrombosis 0.25%.

Pre-PCI/ Post-PCI	No/No	Yes/No	No/Yes	Yes/Yes	P Value
Mean Number of Stents	1.17	1.2	1.33	1.5	.001
Mean Post-PCI FFR	0.89	0.89	0.89	0.86	.003
Mean Procedure Duration, mins	88	90	94	106	.0043
Mean Post-PCI MLA, mm ²	6.1	5.2	5.3	5.0	.004
30-Day Events					
MACE	10.9%	9.8%	12.5%	0	.077
MI ^a	10.2%	8.6%	12.5%	0	.017

Incidence and Clinical Significance of Poststent OCT Findings: 900 lesions (786 patients)


	No-DoCE (795 lesions)	DoCE (39 lesions)	<i>P</i> Value
Stent edge dissection	230 (28.9)	12 (30.8)	0.789
Proximal stent edge dissection	125 (15.7)	9 (23.1)	0.202
Distal stent edge dissection	126 (15.8)	8 (20.5)	0.430
Instent dissection	535 (67.3)	24 (61.5)	0.488
Incomplete stent apposition	305 (38.4)	14 (35.9)	0.765
Instent tissue protrusion	767 (96.5)	39 (100)	0.636
Smooth protrusion	735 (92.5)	37 (94.9)	0.688
Disrupted fibrous tissue protrusion	490 (61.6)	21 (53.8)	0.330
Irregular protrusion	416 (52.3)	29 (74.4)	0.003
Thrombus	302 (38.0)	20 (51.3)	0.132
Stent underexpansion	296 (37.2)	13 (33.3)	0.656
Small MSA	321 (40.4)	23 (59.0)	0.039
Minimal stent area, mm ²	5.8±2.0	5.4±2.0	0.264
Minimal lumen area, mm ²	5.9±2.0	5.4±2.0	0.224
Proximal reference area, mm ²	7.8±3.0	7.2±3.2	0.392
Distal reference area, mm ²	6.3±2.7	5.9±2.9	0.429

Device-oriented clinical endpoints (DOCE):

Cardiac death,
Target vessel-related MI,
TLR,
Stent thrombosis.

Minimal stent area associated with outcome

A. Drug eluting stent



Best cut off 5.0 mm²

AUC 0.626


Sensitivity 65.4 %

Specificity 58.0 %

PPV 5.6 %

NPV 97.8 %

B. Bare metal stent



Best cut off 5.6 mm²

AUC 0.591






Sensitivity 53.8 %

Specificity 69.7 %


PPV 17.5 %

NPV 92.7 %


Poststent OCT findings



TLR event free survival distributions of lesions




Number at risk	0	3	6	9	12
Irregular Protrusion (-)	416	397	389		
Irregular Protrusion (+)	484	459	445		





Number at risk	0	3	6	9	12
Small MSA (-)	536	506	490		
Small MSA (+)	364	350	344		

OCT results for subacute thrombosis



21 definite
subacute ST

OCT results in subacute thrombosis & control



Clinical events of stent malapposition

Acute stent malapposition: 62%
 Late-persistent stent malapposition: 31%
 Late-acquired stent malapposition: 15%.

	Overall Patients (N=351)	Both Late-Persistent and Late-Acquired Stent Malapposition (n=23)	Late-Acquired Stent Malapposition Alone (n=31)	Late-Persistent Stent Malapposition Alone (n=45)	No Stent Malapposition (n=252)	PValue
Follow-up duration after PCI, mo	28.6±10.3	24.3±4.3	27.7±10.0	28.4±9.2	29.1±10.8	0.175
Follow-up duration after follow-up OCT, mo	22.8±10.4	18.4±4.4	22.0±10.4	22.6±8.9	23.3±10.9	0.180
Composite of clinical events	10 (2.9%)	0 (0%)	1 (3.2%)	1 (2.2%)	8 (3.2%)	1.0
Cardiovascular death	1 (0.3%)	0 (0%)	0 (0%)	0 (0%)	1 (0.4%)	1.0
Nonfatal myocardial infarction	1 (0.3%)	0 (0%)	0 (0%)	0 (0%)	1 (0.4%)	1.0
Stent thrombosis	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1.0
Target lesion revascularization	8 (2.3%)	0 (0%)	1 (3.2%)	1 (2.2%)	6 (2.4%)	0.900

Post-procedure OCT & clinical outcome

JACC: CARDIOVASCULAR IMAGING

© 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION

PUBLISHED BY ELSEVIER INC.

VOL. 8, NO. 11, 2015

ISSN 1936-878X/\$36.00

<http://dx.doi.org/10.1016/j.jcmg.2015.08.013>

Clinical Impact of OCT Findings During PCI




The CLI-OPCI II Study

Francesco Prati, MD, PhD,*† Enrico Romagnoli, MD, PhD,† Francesco Burzotta, MD, PhD,‡ Ugo Limbruno, MD,§
Laura Gatto, MD,*† Alessio La Manna, MD,|| Francesco Versaci, MD,¶ Valeria Marco, RN,† Luca Di Vito, MD, PhD,*
Fabrizio Imola, MD,* Giulia Paoletti, RN,† Carlo Trani, MD,‡ Corrado Tamburino, MD,|| Luigi Tavazzi, MD,#
Gary S. Mintz, MD**

1,002 lesions (832 patients)

OCT criteria of suboptimal stent implantation



Suboptimal OCT findings


	All Lesions (N = 984)	Lesion With MACE (n = 125)	Lesion Without MACE (n = 859)	p Value
Suboptimal OCT criteria				
Minimum in-stent lumen area <4.5 mm ²	230 (23.4)	51 (40.8)	179 (20.8)	<0.001
In-stent lumen underexpansion†	233 (23.7)	38 (30.4)	195 (22.7)	0.07
Malapposition >200 μm	485 (49.3)	63 (50.4)	422 (49.1)	0.85
Intrastent plaque/thrombus protrusion >500 μm	289 (29.4)	38 (30.4)	251 (29.2)	0.83
Edge dissection >200 μm	125 (12.7)	25 (20.0)	100 (11.6)	0.013
Distal dissection	69 (7.0)	20 (16.0)	49 (5.7)	<0.001
Proximal dissection	65 (6.6)	8 (6.4)	57 (6.6)	0.92
Reference narrowing‡	74 (7.5)	38 (30.4)	36 (4.2)	<0.001
Distal narrowing	57 (5.8)	28 (22.4)	29 (3.4)	<0.001
Proximal narrowing	24 (2.4)	14 (11.2)	10 (1.2)	<0.001
At least 1 predictive OCT criterion§	305 (31.0)	74 (59.2)	231 (26.9)	<0.001

Suboptimal OCT deployment & clinical outcome

	All Patients (N = 832)	Patients With Suboptimal OCT Deployment* (n = 254)	Patients With Optimal OCT Deployment (n = 578)	HR (95% CI)	p Value
MACE	105 (12.6)	64 (25.2)	41 (7.1)	4.41 (2.9-6.8)	0.001
Death	24 (2.9)	11 (4.3)	13 (2.2)	1.97 (0.9-4.5)	0.104
Myocardial infarction	64 (7.7)	42 (16.5)	22 (3.8)	5.01 (2.9-8.6)	0.001
Periprocedural	22 (2.6)	11 (4.3)	11 (1.9)	2.33 (1.0-5.5)	0.050
During follow-up	42 (5.1)	31 (12.2)	11 (1.9)	7.17 (3.5-14.5)	0.001
Target lesion revascularization	56 (6.7)	42 (16.5)	14 (2.4)	7.98 (4.3-14.9)	0.001
Stent thrombosis	30 (3.6)	26 (10.2)	4 (0.7)	16.36 (5.6-47.4)	0.001
Days of follow-up	319 (123-576)	312 (118-584)	324 (129-575)	-	0.536

*Either in-stent minimum lumen area <4.5 mm², dissection >200 mm at the distal stent edge, or distal or proximal reference narrowing

Survival free of MACE according to optimal versus nonoptimal stent




*Either in-stent minimum lumen area $<4.5 \text{ mm}^2$, dissection $>200 \text{ mm}$ at the distal stent edge, or distal or proximal reference narrowing

Chest pain at exertion
Aggravation, 1 week ago

Case 1: M/61


Hypertension (+)
Dyslipidemia (+)



Stenting at pLAD




Balloon angioplasty





Stenting


Coronary angiography after stenting



Oops... by final OCT




9 months later



ILUMIEN III: Optimize PCI

COMING SOON!



Scope: Up to 35 sites (US, EMEA, Japan)

420 randomized subjects

Endpoint: Safety/Efficacy Study

Primary Efficacy Endpoint (powered).

: Post-PCI MSA assessed by OCT in each randomized arm



OPTical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON (OPINION)

This study is ongoing, but not recruiting participants.

Sponsor:

Translational Research Informatics Center, Kobe, Hyogo, Japan

Collaborator:

Wakayama Medical University

Information provided by (Responsible Party):

Translational Research Informatics Center, Kobe, Hyogo, Japan

ClinicalTrials.gov Identifier:

NCT01873027

First received: May 26, 2013

Last updated: August 11, 2014

Last verified: August 2014

[History of Changes](#)

Primary Outcome Measures:

- Target Vessel Failure (TVF) [Time Frame: 12 months after PCI] [Designated as safety issue: Yes]

The composite endpoint comprised of cardiac death, target vessel-related myocardial infarction (MI) and clinically-driven target vessel revascularization (TVR)

Enrollment:

829

Study Start Date:

June 2013

Estimated Study Completion Date:

December 2015

Estimated Primary Completion Date:

December 2015 (Final data collection date for primary outcome measure)

Take Home Messages

- OCT allow high-resolution images of pre-, peri- and post-procedure, so we can assess lesion characteristics, stent optimization, and procedure complications with it.
- Abnormal post-stent OCT findings are frequent.
- Procedural strategy has been influenced by OCT findings of both pre-PCI and post-PCI in the majority of patients.
- The potential impact of OCT guidance to optimize PCI outcome seems promising and requires further investigations in large-scale prospective trials.